Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01086215 · ClinicalTrials.gov registry record

Registry of AngioJet Use in the Peripheral Vascular System

A clinical trial of Peripheral Vascular Disease and Venous Thrombosis, sponsored by Boston Scientific Corporation.

Completed
Registry status
500
Enrollment target
20
Study locations

NCT01086215: Completed study of Peripheral Vascular Disease and Venous Thrombosis, sponsored by Boston Scientific Corporation.

NCT01086215 is a study of Peripheral Vascular Disease and Venous Thrombosis that has completed, run by Boston Scientific Corporation. The registered enrollment target is 500 participants, above the 262-participant average among 25 other Peripheral Vascular Disease trials with a reported enrollment target (91% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01086215, a study of Peripheral Vascular Disease and Venous Thrombosis, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
500 participants
Enrollment target
20
Study locations

Study Summary

The Registry involves the collection of information for research and educational purposes only on the use of AngioJet in the peripheral vascular system.

Primary Outcome

From the Index Procedure's Baseline (pre-endovascular treatment) and Final (post-endovascular treatment) angiograms/venograms, each vessel was assigned a value by the treating physician. 1. complete occlusion (\>90% occlusion); 2. substantial occlusion (50-90% occlusion OR \<50% occlusion and \>3cm in length); 3. partial occlusion (\<50% occlusion AND \<3cm in length) 4. patent (without visable thrombus or occlusion) The levels of change (improvement) were calculated by subtracting the baseline

Study Locations (20)

Florida

  • University of Florida- College of Medicine - Jacksonville
  • First Coast Cardiovascular Institute - Jacksonville
  • Sacred Heart Hospital - Pensacola

Louisiana

  • Cardiovascular Consultants - Bossier City
  • Terrebonne General Medical Center - Houma
  • Regional Medical Center of Acadiana - Lafayette

Ohio

  • Cleveland Clinic - Cleveland
  • Grant Medical Center - Columbus
  • Good Samaritan Hospital - Dayton

Arizona

  • Phoenix Heart, PLLC - Glendale
  • John C. Lincoln Deer Valley Hospital - Phoenix

North Carolina

  • Duke University Medical Center - Durham
  • Forsyth Medical Center - Winston-Salem

California

  • Good Samaritan Hospital - Los Angeles

Delaware

  • Christiana Care Health System - Newark

Georgia

  • Chris Recknor PC - Gainesville

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2010-01
Est. Completion 2013-09
Boston Scientific Corporation

280 total trials

What the finished NCT01086215 record still lists

NCT01086215 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 262-participant average among 25 other Peripheral Vascular Disease trials with a reported enrollment target (91% higher).

The record links to 3 conditions, with Peripheral Vascular Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01086215 names 20 study sites across 12 states, led by Florida, Louisiana, Ohio.

Frequently Asked Questions

What is clinical trial NCT01086215 about?

NCT01086215 is a clinical study titled "Registry of AngioJet Use in the Peripheral Vascular System". The Registry involves the collection of information for research and educational purposes only on the use of AngioJet in the peripheral vascular system.

What is the current status of trial NCT01086215?

This trial is currently completed. The enrollment target is 500 participants. The study started on 2010-01. Estimated completion is 2013-09.

What conditions does trial NCT01086215 study?

This clinical trial studies the following conditions: Peripheral Vascular Disease, Venous Thrombosis, Embolism and Thrombosis.

Who is sponsoring clinical trial NCT01086215?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01086215 being conducted?

This trial has 20 study locations across Arizona, California, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Vascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01086215's enrollment target sits among peer trials

500 3rd of 25 higher than 23 of 25 other Peripheral Vascular Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Peripheral Vascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01086215, the US trial registry maintained by the National Library of Medicine. NCT01086215 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.